HPTN Publications
Looking to submit your manuscript for review?
Your manuscript can be reviewed by our Manuscript Review committee. Get the submission form.
Filter publications by:
McKinstry LA, Zerbe A, Farrior J, Kurth AE, Stanton J, Li M, Elion R, Leider J, Branson B, El-Sadr WM, Hanscom B, for the HPTN 065 Study, Kurth A, Li Maoji . A Randomized-Controlled Trial of Computer-based Prevention Counseling for HIV-Positive Persons (HPTN 065). 2017
2017
HPTN 065
Melendez JH, Hardick J, Barnes M, Barnes P, Geddes CD, Gaydos CA . Molecular Characterization of Markers Associated With Antimicrobial Resistance in Neisseria gonorrhoeae Identified From Residual Clinical Samples. Sex Transm Dis. 2018, 45: 312-315
2018
Sex Transm Dis
Metzger DS, Donnell D, Celentano DD, Jackson JB, Shao Y, Aramrattana A, Wei L, Fu L, Ma J, Lucas GM, Chawarski M, Ruan Y, Richardson P, Shin K, Chen RY, Sugarman J, Dye BJ, Rose SM, Beauchamp G, Burns DN; HPTN 058 Protocol Team, Burns DN, HPTN 058 Protocol Team . Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine-Naloxone: HIV Prevention Trials Network 058. JAIDS. 2015, 68: 554-61
2015
JAIDS
HPTN 058
Meyer D, Lowensen K, Perrin N, et al, Diane Meyer ,Kelly Lowensen,Nancy Perrin,Ayana Moore,Shruti H. Mehta,Cheryl R. Himmelfarb,Thomas V. Inglesby,Jacky M. Jennings,Alexandra K. Mueller,Jessica N. LaRicci,Woudase Gallo,Adam P. Bocek,Jason E. Farley . An evaluation of the impact of social and structural determinants of health on forgone care during the COVID-19 pandemic in Baltimore, Maryland. PLoS One. 2024
2024
PLoS One
CoVPN 5002
Mgodi NM, Takuva S, Edupuganti S, Karuna S, Andrew P, Lazarus E, Garnett P, Shava E, Mukwekwerere PG, Karg C, Tindale I, Greene E, Luthuli N, Baepanye K, Hural J, Gomez Lorenzo MM, Burns D, Miner MD, Ledgerwood J, Mascola JR, Donnell D, Cohen MS, Corey L, HVTN 703/HPTN 081 Team . A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings. J Acquir Immune Defic Syndr. 2021, 87: 680-687
2021
J Acquir Immune Defic Syndr
HVTN 703/HPTN 081
Miller L, Prieto Merino D, Baisley K, Hayes R. . Hidden heterogeneity: Uncovering patterns of adherence in microbicide trials for HIV prevention.. PLoS One. , 17: e0267011
2022
PLoS One
HPTN 035
Miller WC, Hoffman IF, Hanscom BS, Ha TV, Dumchev K, Djoerban Z, Rose SM, Latkin CA, Metzger DS, Lancaster KE, Go VF, Dvoriak S, Mollan KR, Reifeis SA, Piwowar-Manning E, Richardson P, Hudgens MG, Hamilton EL, Sugarman J, Eshleman SH, Susami H, Chu VA, Djauzi S, Kiriazova T, Bui DD, Strathdee SA, Burns DN . A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet. 2018, 392: 747-759
2018
Lancet
HPTN 074
Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, Pinto J, Santos B, Parsons T, Kearney B, Emel L, Herron C, Richardson P, Hudelson SE, Eshleman SH, George K, Fowler MG, Sato P, Mofenson L; HPTN 057 Protocol Team . Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014, 65: 33-41
2014
J Acquir Immune Defic Syndr
HPTN 057